C12N 2760/18523
Virus like particles [vlp]
Official title: Virus like particles [VLP]
C12N2760/18523 (Virus like particles [vlp]) appears on 34 US grants and 51 published applications in this corpus.
Search patents in C12N- Granted patents
- 34
- Published applications
- 51
- Assignees
- 35
- Inventors
- 114
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 2 |
| 2008 | 0 | 1 |
| 2009 | 0 | 2 |
| 2010 | 0 | 2 |
| 2011 | 1 | 3 |
| 2012 | 0 | 1 |
| 2013 | 3 | 2 |
| 2014 | 1 | 4 |
| 2015 | 3 | 4 |
| 2016 | 2 | 0 |
| 2017 | 5 | 3 |
| 2018 | 2 | 2 |
| 2019 | 0 | 4 |
| 2020 | 2 | 2 |
| 2021 | 3 | 2 |
| 2022 | 2 | 4 |
| 2023 | 0 | 5 |
| 2024 | 3 | 2 |
| 2025 | 5 | 2 |
| 2026 | 2 | 4 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Virus-like particles containing RSV antigen protein and vaccines using the same12 May 2026US 12,622,958 B2University-Industry Cooperation Group of Kyung Hee University
- Chimeric RSV and HMPV F proteins, immunogenic compositions, and methods of use10 Feb 2026US 12,544,436 B2Children's Healthcare of Atlanta, Inc.
- Lipopeptide building blocks and synthetic virus-like particles11 Nov 2025US 12,465,633 B2UniversitäT ZüRich
- Vaccine composition7 Oct 2025US 12,433,944 B2SpyBiotech Limited
- RSV virus-like particles and methods of use thereof29 Jul 2025US 12,370,252 B2Children's Healthcare of Atlanta, Inc.
- Lipopeptide building blocks and synthetic virus-like particles21 May 2026US 2026/0137767 A1UniversitäT ZüRich
- Mutant of rsv f protein30 Apr 2026US 2026/0117202 A1National Vaccine and Serum Institute(Nvsi)
- Vaccine composition8 Jan 2026US 2026/0007740 A1SpyBiotech Limited
- Rsv virus-like particles and methods of use thereof1 Jan 2026US 2026/0000750 A1Children's Healthcare of Atlanta, Inc.
- Prefusion rsv f proteins and their use25 Dec 2025US 2025/0388627 A1The United States of America, as represented by the Secretary, Department of Health and Human Servic
Most cited
By later US patents
- Modified RSV F proteins and methods of their use23US 10,022,437 B2Novavax, Inc. · 2018
- Modified RSV F proteins and methods of their use20US 8,715,692 B2Novavax, Inc. · 2014
- Avian influenza chimeric VLPS18US 8,551,756 B2Novavax, Inc. · 2013
- Virus-like particles as vaccines for paramyxovirus12US 7,951,384 B2University of Massachusetts · 2011
- Modified RSV F proteins and methods of their use11US 9,675,685 B2Novavax, Inc. · 2017